Hiroshima

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Asthma5 trials
• Hepatitis B3 trials
• Lupus (SLE)2 trials
• Systemic sclerosis (scleroderma)2 trials
• Dermatomyositis and polymyositis (myositis)1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Primary biliary cholangitis1 trial
• Rheumatoid arthritis1 trial
• Sjögren's disease1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 38 trials
• Phase 23 trials
• Phase 11 trial
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed7 trials
• Active, not recruiting5 trials
• Recruiting3 trials

Lead sponsor

• GlaxoSmithKline15 trials

Running trials

• Recruiting

  A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

  NCT07371468· Phase 1· GlaxoSmithKline· Source

  Contact: Shintaro Hirata (principal investigator)

• Active, not recruiting

  A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

  NCT06748053· Phase 2· GlaxoSmithKline· Source

• Recruiting

  A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

  NCT06716606· Phase 3· GlaxoSmithKline· Source

  Contact: Tomohiro Sugimoto (principal investigator)

• Active, not recruiting

  Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

  NCT06372496· Phase 4· GlaxoSmithKline· Source

• Recruiting

  A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  NCT05878717· Phase 2/3· GlaxoSmithKline· Source

  Contact: Tomohiro Sugimoto (principal investigator)

• Active, not recruiting

  Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

  NCT04954859· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

  NCT04915755· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Linerixibat Long-term Safety, and Tolerability Study

  NCT04167358· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Systemic sclerosis (scleroderma)2 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Lupus (SLE)1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting

Closed trials

• Completed

  Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· Phase 2· GlaxoSmithKline· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

  NCT05630807· Phase 3· GlaxoSmithKline· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

  NCT05630820· Phase 3· GlaxoSmithKline· Source

• Completed

  An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

  NCT05243680· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718103· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source

• Completed

  BENLYSTA® Special Drug Use Investigation

  NCT03370263· GlaxoSmithKline· Source